title: Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects.
abstract: Vitamin K is required for the carboxylation of Gla-proteins in the liver (coagulation factors) and extra-hepatic tissues, such as bone (osteocalcin, OC), and arterial wall (matrix Gla-protein, MGP). Although the coagulation factors are essentially fully carboxylated under normal conditions, 10-40 % of OC and MGP remains undercarboxylated. We were therefore interested to study the dose-response effects of extra intake of menaquinones on the carboxylation of the extra-hepatic Gla-proteins. A total of forty-two healthy Dutch men and women aged between 18 and 45 years were randomised into seven groups to receive: placebo capsules or menaquinone-7 (MK-7) capsules at a daily dose of 10, 20, 45, 90, 180 or 360 μg. Circulating uncarboxylated OC (ucOC), carboxylated OC (cOC) and desphospho-uncarboxylated MGP were measured by ELISA. The ucOC:cOC ratio was calculated from circulating ucOC and cOC values. Endogenous thrombin potential and peak height were determined by calibrated automated thrombography. To increase the statistical power, we collapsed the treatment groups into three dosage groups: placebo, low-dose supplementation (doses below RDA, Commission Directive 2008/100/EC), and high-dose supplementation (doses around RDA, Commission Directive 2008/100/EC). MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP. No adverse effects on thrombin generation were observed. Extra MK-7 intake at nutritional doses around the RDA (Commission Directive 2008/100/EC) improved the carboxylation of the extra-hepatic vitamin K-dependent proteins. Whether this improvement contributes to public health, i.e. increasing the protection against age-related diseases needs further investigation in specifically designed intervention trials.
authors.affiliation: VitaK & Cardiovascular Research Institute Maastricht, Maastricht University, Oxfordlaan 70, Maastricht, The Netherlands. e.theuwissen@vitak.com
authors.forename: Elke
authors.initials: E
authors.lastname: Theuwissen
authors.forename: Ellen C
authors.initials: EC
authors.lastname: Cranenburg
authors.forename: Marjo H
authors.initials: MH
authors.lastname: Knapen
authors.forename: Elke J
authors.initials: EJ
authors.lastname: Magdeleyns
authors.forename: Kirsten J
authors.initials: KJ
authors.lastname: Teunissen
authors.forename: Leon J
authors.initials: LJ
authors.lastname: Schurgers
authors.forename: Egbert
authors.initials: E
authors.lastname: Smit
authors.forename: Cees
authors.initials: C
authors.lastname: Vermeer
mesh_terms: D000328:Adult; D000465:Algorithms; D001777:Blood Coagulation; D001780:Blood Coagulation Tests; D003653:Decarboxylation; D019587:Dietary Supplements / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006490:Hemostatics / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D009752:Nutritional Status; D015675:Osteocalcin / Q000097:blood / Q000378:metabolism; D010865:Pilot Projects; D014812:Vitamin K / Q000097:blood; D024482:Vitamin K 2 / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D014813:Vitamin K Deficiency / Q000097:blood / Q000178:diet therapy* / Q000378:metabolism; D055815:Young Adult
chemical_list: D006490:Hemostatics; D015675:Osteocalcin; D024482:Vitamin K 2; D014812:Vitamin K; C062629:menaquinone 7